Stefania Chiappetta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6369488/publications.pdf

Version: 2024-02-01

1477746 1588620 12 69 6 8 citations h-index g-index papers 12 12 12 212 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection—authors' response. Journal of Antimicrobial Chemotherapy, 2017, 72, 1549-1550.	1.3	1
2	Immunosenescence and hurdles in the clinical management of older HIV-patients. Virulence, 2017, 8, 508-528.	1.8	9
3	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. Journal of Antimicrobial Chemotherapy, 2017, 72, 632-633.	1.3	9
4	The use of circulating cathodic antigen rapid test and serology for diagnosis of active Schistosoma mansoni infection in migrants in Italy, a non-endemic country: a cross sectional study. Memorias Do Instituto Oswaldo Cruz, 2017, 112, 452-455.	0.8	7
5	Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up. Journal of Clinical Virology, 2016, 85, 86-89.	1.6	2
6	Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1627-1631.	1.3	5
7	Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets. PLoS ONE, 2015, 10, e0140435.	1.1	11
8	HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications. ISRN Virology, 2014, 2014, 1-6.	0.5	0
9	Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e27-e29.	0.9	3
10	Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient. International Journal of STD and AIDS, 2013, 24, 980-982.	0.5	3
11	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 1686-1688.	1.3	12
12	Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4+ Changes in Maraviroc-Treated HIV-Infected Patients. PLoS ONE, 2012, 7, e37032.	1.1	7